$STRO
SUTRO BIOPHARMA, INC. Stock $stro

$stro Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024035949 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$13.01M	$113.7M	$153.7M
YoY Change	2.64%	1217.44%	126.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.72M	$16.80M	$62.58M
YoY Change	-17.99%	14.17%	5.11%
% of Gross Profit
Research & Development	$56.88M	$53.77M	$180.4M
YoY Change	44.36%	24.64%	31.53%
% of Gross Profit
Depreciation & Amortization	$1.761M	$1.726M	$6.816M
YoY Change	9.04%	12.96%	19.58%
% of Gross Profit
Operating Expenses	$69.60M	$70.57M	$243.0M
YoY Change	26.75%	21.98%	23.53%
Operating Profit	-$56.59M		-$89.28M
YoY Change	33.98%		-30.76%
Interest Expense	$5.562M	$9.912M	$13.25M
YoY Change	-174.98%	-32.24%	8.24%
% of Operating Profit
Other Income/Expense, Net	-$7.184M	-$6.192M	-$12.57M
YoY Change
Pretax Income	-$58.21M	$46.87M	-$88.60M
YoY Change	17.23%	-235.49%	-24.08%
Income Tax	$0.00	$15.81M	$18.19M
% Of Pretax Income		33.72%
Net Earnings	-$58.21M	$31.07M	-$106.8M
YoY Change	16.31%	-189.8%	-10.41%
Net Earnings / Revenue	-447.52%	27.32%	-69.47%
Basic Earnings Per Share	-$0.95		-$1.78
Diluted Earnings Per Share	-$0.95	$0.51	-$1.78
COMMON SHARES
Basic Shares Outstanding	62.44M	60.95M	60.16M
Diluted Shares Outstanding	61.46M		60.16M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$313.2M	$375.6M	$375.6M
YoY Change	13.28%	12.34%	12.34%
Cash & Equivalents	$65.22M	$69.27M	$69.27M
Short-Term Investments	$248.0M	$306.4M	$306.4M
Other Short-Term Assets	$10.06M	$9.846M	$9.846M
YoY Change	-43.13%	-15.61%	-15.61%
Inventory
Prepaid Expenses
Receivables	$31.30M	$36.08M	$36.08M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$354.6M	$421.5M	$421.5M
YoY Change	16.61%	19.37%	19.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.63M	$44.76M	$44.76M
YoY Change	-14.15%	81.78%	-12.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.739M	$4.439M	$4.439M
YoY Change	76.58%	139.3%	62.78%
Total Long-Term Assets	$48.82M	$49.19M	$49.19M
YoY Change	-9.51%	-8.55%	-8.55%
TOTAL ASSETS
Total Short-Term Assets	$354.6M	$421.5M	$421.5M
Total Long-Term Assets	$48.82M	$49.19M	$49.19M
Total Assets	$403.4M	$470.7M	$470.7M
YoY Change	12.68%	15.68%	15.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.511M	$9.440M	$9.440M
YoY Change	48.5%	96.79%	96.79%
Accrued Expenses	$7.077M	$59.58M	$59.58M
YoY Change	11.34%	353.35%	83.37%
Deferred Revenue	$20.50M	$20.67M
YoY Change	19.29%	23.31%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.061M	$4.061M
YoY Change	-100.0%	-67.51%	-67.51%
Total Short-Term Liabilities	$79.51M	$93.75M	$93.75M
YoY Change	33.66%	40.87%	40.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$1.694M	$227.3M	$227.3M
YoY Change	-98.5%	190942.86%	90.12%
Total Long-Term Liabilities	$1.694M	$227.3M	$227.3M
YoY Change	-98.5%	5744.24%	84.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.51M	$93.75M	$93.75M
Total Long-Term Liabilities	$1.694M	$227.3M	$227.3M
Total Liabilities	$305.4M	$321.1M	$321.1M
YoY Change	76.93%	69.09%	69.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$617.6M	-$559.4M
YoY Change	22.86%	23.6%
Common Stock	$715.8M	$709.0M
YoY Change	4.01%	5.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$98.02M	$149.6M	$149.6M
YoY Change
Total Liabilities & Shareholders Equity	$403.4M	$470.7M	$470.7M
YoY Change	12.68%	15.68%	15.68%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$58.21M	$31.07M	-$106.8M
YoY Change	16.31%	-189.8%	-10.41%
Depreciation, Depletion And Amortization	$1.761M	$1.726M	$6.816M
YoY Change	9.04%	12.96%	19.58%
Cash From Operating Activities	-$64.74M	$14.07M	-$111.6M
YoY Change	6.15%	-158.98%	-3245.0%
INVESTING ACTIVITIES
Capital Expenditures	$446.0K	$1.445M	$4.315M
YoY Change	-52.65%	-57.08%	-45.09%
Acquisitions
YoY Change
Other Investing Activities	$64.55M	-$22.07M	$391.0K
YoY Change	-5.62%	-36.06%	-101.44%
Cash From Investing Activities	$64.11M	-$23.51M	-$3.924M
YoY Change	-4.96%	-37.93%	-88.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.29M
YoY Change			-78.17%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.429M	-3.126M	137.6M
YoY Change	-139.15%	-125.58%	184.71%
NET CHANGE
Cash From Operating Activities	-64.74M	14.07M	-111.6M
Cash From Investing Activities	64.11M	-23.51M	-3.924M
Cash From Financing Activities	-3.429M	-3.126M	137.6M
Net Change In Cash	-4.065M	-12.57M	22.01M
YoY Change	-126.71%	-74.63%	30.72%
FREE CASH FLOW
Cash From Operating Activities	-$64.74M	$14.07M	-$111.6M
Capital Expenditures	$446.0K	$1.445M	$4.315M
Free Cash Flow	-$65.19M	$12.63M	-$115.9M
YoY Change	5.25%	-146.38%	2590.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001382101
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#EquitySecuritiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#EquitySecuritiesMember
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#EquitySecuritiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#EquitySecuritiesMember
CY2022Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#EquitySecuritiesMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24621000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22815000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26443000
CY2023	dei	Entity File Number EntityFileNumber	001-38662
CY2023	dei	Entity Registrant Name EntityRegistrantName	SUTRO BIOPHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-0926186
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	111 Oyster Point Blvd
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	881-6500
CY2023	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2023	dei	Trading Symbol TradingSymbol	STRO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	278300000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62441963
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69268000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47254000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	264413000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	255090000
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	41937000
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	32020000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36078000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7122000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9846000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11667000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	421542000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	353153000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21940000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3567000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1855000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2023Q4	us-gaap	Assets Assets	470736000
CY2022Q4	us-gaap	Assets Assets	406944000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9440000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4797000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14686000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13142000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20666000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16759000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6420000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4585000
CY2023Q4	us-gaap	Debt Current DebtCurrent	4061000
CY2022Q4	us-gaap	Debt Current DebtCurrent	12500000
CY2023Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	38473000
CY2022Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	14764000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93746000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66547000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	53379000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	89885000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23154000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29574000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3771000
CY2023Q4	stro	Deferred Royalty Obligation Related To Sale Of Future Royalties Noncurrent DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent	149114000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1694000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	119000
CY2023Q4	us-gaap	Liabilities Liabilities	321087000
CY2022Q4	us-gaap	Liabilities Liabilities	189896000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61009829
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61009829
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57499541
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57499541
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	61000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	708975000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	670223000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-618000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-559408000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-452615000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	149649000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	217048000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	470736000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406944000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153731000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67772000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61880000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	180425000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	137171000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	104400000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	62584000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59544000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56004000
CY2023	us-gaap	Operating Expenses OperatingExpenses	243009000
CY2022	us-gaap	Operating Expenses OperatingExpenses	196715000
CY2021	us-gaap	Operating Expenses OperatingExpenses	160404000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-89278000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-128943000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-98524000
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	14510000
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3455000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	577000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	9917000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	12130000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4454000
CY2023	stro	Non Cash Interest Expense Related To The Sale Of Future Royalties NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties	12570000
CY2023	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-11180000
CY2022	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-3346000
CY2021	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-3137000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88601000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116704000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-105538000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18192000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2500000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-106793000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.78
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.78
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.29
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60163542
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60163542
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50739185
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50739185
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46119089
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46119089
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-106793000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	639000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-443000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106154000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119508000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105981000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	332048000
CY2021	stro	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	2485000
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	7000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1765000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	987000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23241000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-443000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	252564000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	268000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1613000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	463000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26304000
CY2022	stro	Stock Issued During Period Value Through At The Market Sale StockIssuedDuringPeriodValueThroughAtTheMarketSale	56270000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-304000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	217048000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	314000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2051000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	490000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24908000
CY2023	stro	Stock Issued During Period Value Through At The Market Sale StockIssuedDuringPeriodValueThroughAtTheMarketSale	11971000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	639000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-106793000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	149649000
CY2023	us-gaap	Profit Loss ProfitLoss	-106793000
CY2022	us-gaap	Profit Loss ProfitLoss	-119204000
CY2021	us-gaap	Profit Loss ProfitLoss	-105538000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6816000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5690000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4844000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	9075000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	364000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2781000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	24908000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	26304000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23241000
CY2023	stro	Noncash Lease Expenses NoncashLeaseExpenses	3628000
CY2022	stro	Noncash Lease Expenses NoncashLeaseExpenses	2598000
CY2021	stro	Noncash Lease Expenses NoncashLeaseExpenses	4929000
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	4074000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	9917000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	12130000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-4454000
CY2023	stro	Non Cash Interest Expense On Deferred Royalty Obligation NonCashInterestExpenseOnDeferredRoyaltyObligation	12570000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-622000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-324000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1230000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28956000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5341000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6895000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-109000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3544000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3959000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4812000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1225000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2708000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1544000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1725000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2594000
CY2023	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	25300000
CY2022	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	6562000
CY2021	stro	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	5866000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-32599000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	93648000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15207000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4585000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1898000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2727000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111616000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3549000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81679000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	460301000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	216671000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	248727000
CY2023	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	434966000
CY2022	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	127960000
CY2021	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	148250000
CY2023	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	25726000
CY2022	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	32799000
CY2021	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	18476000
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	28739000
CY2023	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	4315000
CY2022	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	7858000
CY2021	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	15323000
CY2022	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	9000
CY2021	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	9000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3924000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35022000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-97315000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11971000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56270000
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	12500000
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	9375000
CY2023	stro	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	136208000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	314000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	268000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2485000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	490000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	463000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	987000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2051000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1613000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1765000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137554000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48313000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3256000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22014000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16840000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-175738000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31286000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207024000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70140000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31286000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1126000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1869000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2046000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	379000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	103000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	214000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	280000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	370000
CY2021	stro	Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification	4227000
CY2023	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	9836000
CY2022	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	5079000
CY2021	stro	Financing Component Associated With Program Fees FinancingComponentAssociatedWithProgramFees	610000
CY2023	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2022	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2021	stro	Stock Received During Period Shares StockReceivedDuringPeriodShares	167780
CY2022Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	7500000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1. Organization and Principal Activities</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Sutro Biopharma, Inc. (the “Company”), is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs. The Company was incorporated on </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">April 21, 2003</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and is headquartered in </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">South San Francisco</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">California</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company operates in </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> business segment, the development of biopharmaceutical products. Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Chief Executive Officer, the Company’s chief operating decision maker, in deciding how to allocate resources and assessing performance. The Company operates and manages its business as one operating segment. The Company’s Chief Executive Officer reviews financial information on an aggregate basis for the purposes of allocating and evaluating financial performance.</span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All of the Company’s long-lived assets are maintained in the United States.</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">At-The-Market Sales</span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,857,410</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">shares of its common stock through its At-the-Market Facility (“ATM Facility”) pursuant to its Open Market Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> dated April 2, 2021 with Jefferies LLC (“Jefferies”), as sales agent (the “Sales Agreement”).</span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, the gross proceeds from these sales were approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, before deducting fees of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has incurred significant losses and has negative cash flows from operations. As of December 31, 2023, there was an accumulated deficit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">559.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. Management expects to continue to incur additional </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">substantial</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> losses in the foreseeable future as a result of the Company’s research and development and other operational activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had unrestricted cash, cash equivalents and marketable securities of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">333.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and equity securities of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, consisting solely of common stock of Vaxcyte, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company believes that its unrestricted cash, cash equivalents, marketable securities and investments in equity securities as of December 31, 2023 will enable the Company to maintain its operations for a period of at least </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> months following the filing date of these financial statements.</span></p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2003-04-21
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-559400000
CY2023	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	false
CY2023Q4	stro	Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue	333700000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69268000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47254000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30414000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70140000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31286000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:2.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Cash and cash equivalents and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk, to the extent of the amounts recorded on the Balance Sheets. The Company minimizes the amount of credit exposure by investing cash that is not required for immediate operating needs in money market funds, government obligations and/or commercial paper with short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:3.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company performs a regular review of its collaborators’ credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, the Company provides for an allowance for credit risks by reserving for specifically identified doubtful accounts, although historically the Company has not experienced credit losses from its accounts receivable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	329540000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	54000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	329561000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	299026000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	626000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	298410000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	110900000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	139500000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	600000
CY2023	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2021	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0807
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	300000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	500000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	600000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	20700000
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64103000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62526000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42163000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37905000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21940000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24621000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6800000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5700000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4800000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1300000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	2400000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2600000
CY2023	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1149
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0872
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3125000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15625000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-936000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-646000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	4061000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	16271000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4061000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	12500000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3771000
CY2023Q4	stro	Debt Instrument Including Interest And Final Payment DebtInstrumentIncludingInterestAndFinalPayment	4126000
CY2023Q4	stro	Debt Instrument Interest Payable DebtInstrumentInterestPayable	43000
CY2023Q4	stro	Debt Instrument Final Payment DebtInstrumentFinalPayment	958000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3125000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7039000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6154000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8355000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	274000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	82000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	117000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	2047000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1610000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	2089000
CY2023	us-gaap	Lease Cost LeaseCost	9360000
CY2022	us-gaap	Lease Cost LeaseCost	7846000
CY2021	us-gaap	Lease Cost LeaseCost	10561000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	7000000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	6200000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	8400000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	8000000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6200000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.108
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.108
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9219000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9533000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8994000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8289000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	36035000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6461000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	29574000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6420000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23154000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2800000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	15165000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3897000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3080000
CY2023Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	38473000
CY2022Q4	stro	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	14764000
CY2023Q4	stro	Percentage Of Interest Rate Amortize Liability PercentageOfInterestRateAmortizeLiability	0.17
CY2023	stro	Non Cash Interest Expense On Deferred Royalty Obligation NonCashInterestExpenseOnDeferredRoyaltyObligation	12600000
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote per share
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15970351
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13804406
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	30000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.807
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.841
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.818
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.835
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.809
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.849
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.036
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.047
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.017
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.042
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.03
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.24
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24908000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26304000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23241000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	16646000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	603000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	943000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2500000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	18192000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2500000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18200000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	2500000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.006
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.412
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.262
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.247
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.051
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.037
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.015
CY2023	stro	Effective Income Tax Rate Reconciliation Foreign Tax Withholding EffectiveIncomeTaxRateReconciliationForeignTaxWithholding	-0.011
CY2022	stro	Effective Income Tax Rate Reconciliation Foreign Tax Withholding EffectiveIncomeTaxRateReconciliationForeignTaxWithholding	-0.021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.037
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.033
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.206
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.021
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37231000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60952000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32800000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	40396000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	46260000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	24481000
CY2023Q4	stro	Deferred Tax Assets Deferred Royalty Obligation DeferredTaxAssetsDeferredRoyaltyObligation	31944000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	15274000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5309000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3849000
CY2023Q4	stro	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	6335000
CY2022Q4	stro	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	7471000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5613000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4562000
CY2022Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	663000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	180766000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	142374000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	167693000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	131228000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13073000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11146000
CY2023Q4	stro	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	4887000
CY2022Q4	stro	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	5783000
CY2023Q4	stro	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	809000
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	7377000
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	5363000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	13073000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11146000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36500000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26200000
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three-year testing period.
CY2023	stro	Period For Cumulative Ownership Change PeriodForCumulativeOwnershipChange	P3Y
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8700000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6400000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.29
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8649000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6409000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4902000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2631000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2255000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1492000
CY2023	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-2550000
CY2022	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-15000
CY2021	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	15000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8730000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8649000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6409000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-106793000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119204000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-105538000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60163542
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60163542
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50739185
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50739185
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46119089
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46119089
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.78
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.78
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13504011
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11547237
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9098287

Files In Submission

Name	View Source	Status
0000950170-24-035949-index-headers.html	Edgar Link	pending
0000950170-24-035949-index.html	Edgar Link	pending
0000950170-24-035949.txt	Edgar Link	pending
0000950170-24-035949-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img141552205_0.jpg	Edgar Link	pending
img141552205_1.jpg	Edgar Link	pending
img141552205_2.jpg	Edgar Link	pending
img141552205_3.jpg	Edgar Link	pending
img141552205_4.jpg	Edgar Link	pending
img163211892_0.jpg	Edgar Link	pending
img216776110_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stro-20231231.htm	Edgar Link	pending
stro-20231231.xsd	Edgar Link	pending
stro-ex10_14.htm	Edgar Link	pending
stro-ex10_24.htm	Edgar Link	pending
stro-ex10_30.htm	Edgar Link	pending
stro-ex10_34.htm	Edgar Link	pending
stro-ex10_43.htm	Edgar Link	pending
stro-ex23_1.htm	Edgar Link	pending
stro-ex31_1.htm	Edgar Link	pending
stro-ex31_2.htm	Edgar Link	pending
stro-ex32_1.htm	Edgar Link	pending
stro-ex32_2.htm	Edgar Link	pending
stro-ex4_2.htm	Edgar Link	pending
stro-ex97_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
stro-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRO
SUTRO BIOPHARMA, INC. Stock $stro

2024 Q1 Form 10-K Financial Statement

#000095017024035949 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO SUTRO BIOPHARMA, INC. Stock $stro

2024 Q1 Form 10-K Financial Statement

#000095017024035949 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO
SUTRO BIOPHARMA, INC. Stock $stro